JP2013507415A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507415A5
JP2013507415A5 JP2012533589A JP2012533589A JP2013507415A5 JP 2013507415 A5 JP2013507415 A5 JP 2013507415A5 JP 2012533589 A JP2012533589 A JP 2012533589A JP 2012533589 A JP2012533589 A JP 2012533589A JP 2013507415 A5 JP2013507415 A5 JP 2013507415A5
Authority
JP
Japan
Prior art keywords
compound
formula
composition
administered
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012533589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/065149 external-priority patent/WO2011054620A1/en
Publication of JP2013507415A publication Critical patent/JP2013507415A/ja
Publication of JP2013507415A5 publication Critical patent/JP2013507415A5/ja
Ceased legal-status Critical Current

Links

JP2012533589A 2009-10-12 2010-10-11 Ｐｉ３ｋ阻害剤とｍｅｋ阻害剤の併用 Ceased JP2013507415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
US61/250,852 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (en) 2009-10-12 2010-10-11 Combinations of a pi3k inhibitor and a mek inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014202819A Division JP5745678B2 (ja) 2009-10-12 2014-10-01 Ｐｉ３ｋ阻害剤とｍｅｋ阻害剤の併用

Publications (2)

Publication Number Publication Date
JP2013507415A JP2013507415A (ja) 2013-03-04
JP2013507415A5 true JP2013507415A5 (https=) 2014-04-24

Family

ID=43072663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012533589A Ceased JP2013507415A (ja) 2009-10-12 2010-10-11 Ｐｉ３ｋ阻害剤とｍｅｋ阻害剤の併用
JP2014202819A Expired - Fee Related JP5745678B2 (ja) 2009-10-12 2014-10-01 Ｐｉ３ｋ阻害剤とｍｅｋ阻害剤の併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014202819A Expired - Fee Related JP5745678B2 (ja) 2009-10-12 2014-10-01 Ｐｉ３ｋ阻害剤とｍｅｋ阻害剤の併用

Country Status (24)

Country Link
US (1) US20110086837A1 (https=)
EP (1) EP2488178B1 (https=)
JP (2) JP2013507415A (https=)
KR (1) KR101489045B1 (https=)
CN (1) CN102740851B (https=)
AR (1) AR078588A1 (https=)
AU (1) AU2010314287A1 (https=)
BR (1) BR112012008483A2 (https=)
CA (1) CA2776944A1 (https=)
CL (1) CL2012000913A1 (https=)
CO (1) CO6531463A2 (https=)
CR (1) CR20120173A (https=)
EC (1) ECSP12011865A (https=)
ES (1) ES2609767T3 (https=)
IL (1) IL219105A0 (https=)
MA (1) MA33974B1 (https=)
MX (1) MX345155B (https=)
NZ (1) NZ599939A (https=)
PE (1) PE20121816A1 (https=)
PH (1) PH12012500709A1 (https=)
RU (1) RU2563193C2 (https=)
TW (1) TWI428336B (https=)
WO (1) WO2011054620A1 (https=)
ZA (1) ZA201202618B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CA2849331A1 (en) 2011-10-13 2013-04-18 Genentech, Inc. Treatment of pharmacological-induced hypochlorhydria
PE20142312A1 (es) * 2011-10-28 2015-01-25 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
AU2013243429A1 (en) * 2012-04-06 2014-10-23 Merck Patent Gmbh Methods for treating cancer using PI3K inhibitor and MEK inhibitor
EP2851078B1 (en) * 2012-04-19 2017-06-07 Kyushu University, National University Corporation Pharmaceutical composition
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CA2879665A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
MX2015001407A (es) 2012-08-02 2015-05-08 Genentech Inc Inmunoconjugados y anticuerpos anti-etbr.
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
JP2016515132A (ja) * 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
SG11201700074YA (en) 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016040806A1 (en) * 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (https=) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
CA2186947A1 (en) * 1994-04-01 1995-10-12 Kazuo Ueda Oxime derivative and bactericide containing the same as active ingredients
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
DZ3401A1 (fr) * 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2517517C (en) * 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8084645B2 (en) * 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
HRP20110498T1 (hr) * 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
CN101528231A (zh) * 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.

Similar Documents

Publication Publication Date Title
JP2013507415A5 (https=)
JP2019510832A5 (https=)
JP2016525097A5 (https=)
JP2013542247A5 (https=)
JP2006182786A5 (https=)
JP2017537126A5 (https=)
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
JP2006523216A5 (https=)
JP2005525345A5 (https=)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2018526376A5 (https=)
JP2014532647A5 (https=)
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
JP2014526503A5 (https=)
JP2008521928A5 (https=)
JP2019511526A5 (https=)
JP2012525393A5 (https=)
JP2011507896A5 (https=)
NZ702826A (en) Oral formulations and lipophilic salts of methylnaltrexone
EA037152B1 (ru) Способ лечения рака
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2014505107A5 (https=)
JP2016529285A5 (https=)
JP2018090566A5 (https=)